Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum S2
- Development stage
- Preclinical
- Lead developer
- Microbiotix
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum S2 is a newly isolated, reactive oxygen species (ROS)-resistant strain of *Bifidobacterium longum* obtained from the feces of a healthy adult in South Korea. Developed by Yonsei University and Microbiotix, it is being investigated as a live biotherapeutic product for the treatment of inflammatory bowel disease (IBD), including colitis. The strain exhibits high antioxidant activity and possesses oxidative response genes (such as LexA and HrcA) that enhance its survival and colonization in the gut under oxidative stress. In preclinical models of murine colitis, *B. longum S2* has demonstrated anti-colitic effects, including weight restoration, reduction of goblet cell loss, improvement of epithelial barrier function, and induction of regulatory T (Treg) cells and M2 macrophages.
- Other names
- B. longum S2Bifidobacterium longum strain S2
02
Targets
AHR (Aryl hydrocarbon receptor)FFAR2HDAC (HDAC family)
Beyond the preview
Go deeper on Bifidobacterium longum S2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum S2.